Trial Profile
Planned Transition to Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy in Renal Allograft Recipients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Nov 2013 Top-line results reported in a Pfizer media release.
- 08 Nov 2013 Status changed from recruiting to completed, as reported by a Pfizer media release.
- 08 Nov 2013 Primary endpoint 'significant difference in percentage of patients with an improvement in glomerular filtration rate over 24 months' has not been met, as reported by a Pfizer media release.